ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

… And Invests In Cancer Therapies

by Michael McCoy
May 4, 2015 | APPEARED IN VOLUME 93, ISSUE 18

Celgene will pay AstraZeneca $450 million to participate in development of MEDI4736, an anti-PD-L1 inhibitor for hematologic malignancies. The pact will focus on combining the AstraZeneca antibody with products in Celgene’s pipeline. Separately, Celgene has paid Northern Biologics, a biotech firm backed by Versant Ventures, $30 million for rights to license oncology antibodies in Northern’s pipeline and to acquire Northern. And Celgene has paid Agios Pharmaceuticals $10 million to expand an earlier pact to develop AG-881, a small molecule in development to treat brain cancer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment